secwatch.observer — SEC 8-K summary
======================================

Issuer:     CTI BIOPHARMA CORP (—)
CIK:        0000891293
Form:       8-K
Filed at:   2023-06-26T23:59:59+00:00
Accession:  0001193125-23-174551
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 2.04, 3.03, 5.01, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sobi completes acquisition of CTI BioPharma at $9.10/share; shares delisted from Nasdaq
--------------------------------------------------------------------------------

- Tender offer expired with 110,640,230 shares (83.8%) validly tendered; merger closed June 26, 2023.
- Shareholders received $9.10 per share in cash; preferred stock converted at $91,000 per share.
- CTI notified Nasdaq, requested trading suspension and Form 25 filing to delist and deregister shares.
- Board replaced: prior directors resigned; new directors are Guido Oelkers, Henrik Stenqvist, Torbjörn Hallberg.
- Credit agreement with Drug Royalty III LP repaid in full and terminated on June 26, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/891293/000119312523174551/0001193125-23-174551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/891293/000119312523174551/d460122d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-174551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer